Trial Profile
A Phase IIa, double-blind, placebo-controlled, randomised, parallel-group study, to investigate the safety, tolerability and anxiolytic effect of the mGluR5 negative allosteric modulator ADX10059 in patients with dental anxiety undergoing dental treatment.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Jul 2017
Price :
$35
*
At a glance
- Drugs Raseglurant (Primary)
- Indications Anxiety
- Focus Therapeutic Use
- Sponsors Addex Therapeutics
- 03 Jan 2008 Status changed from in progress to completed
- 03 Jan 2008 Primary endpoint not met; data reported by Addex in a company media release.
- 24 Apr 2007 New trial record.